Effect of rhBNP on CMD in Patients With STEMI After PPCI

NCT ID: NCT05723315

Last Updated: 2023-02-10

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 160 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-02-20
• Study Completion Date: 2025-12-20

Brief Summary

The target population of this interventional study was STEMI patients. Primary discussion: Early rhBNP reduces microcirculation obstruction in STEMI patients undergoing primary PCI

Detailed Description

Direct percutaneous coronary intervention is the preferred reperfusion strategy for acute ST-segment elevation myocardial infarction. During the opening of infarct-related vessels, 5%-50% of patients showed slow flow or no reflow and other coronary microcirculation dysfunction, which aggravated myocardial injury and increased the incidence and mortality of heart failure. Studies have shown that recombinant human brain natriuretic peptide (rhBNP) can reduce reperfusion injury and reduce myocardial infarction area CMD. Prolonged ischemia leads to rapid depletion of intracellular ATP and tissue metabolic acidosis. Blood flow irrigation during reperfusion leads to decreased levels of ATP precursors, calcium overload in mitochondria, release of a large number of inflammatory factors and oxygen free radicals, which can lead to injury or death of myocardial and endothelial cells. rhBNP can enhance the activity of antioxidant enzymes, reduce the irreversible oxidative damage caused by free radicals to myocardium, reduce the myocardial infarction area during ischemia reperfusion, and may reduce the reperfusion injury and protect the viable myocardium.

Conditions

STEMI

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Experimental Group 1

The experimental group was given neoptin within 3h after PCI for 72 hours (first at 1.5μg /kg intravenous load, then at 0.015μg /kg/min).

Group Type: EXPERIMENTAL

recombinant human B-type natriuretic peptide

Intervention Type: DRUG

The recombinant human B-type natriuretic peptide produces physiological effects by imitating endogenous B-type natriuretic peptide

Control Gruop

The experimental group was given an intravenous infusion of the same amount of normal saline

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

recombinant human B-type natriuretic peptide

The recombinant human B-type natriuretic peptide produces physiological effects by imitating endogenous B-type natriuretic peptide

Intervention Type: DRUG

Other Intervention Names

rhBNP

Eligibility Criteria

Inclusion Criteria

• STEMI
• PPCI within 24 hours of symptom onset
• Target vessel QFR-MR>250mm Hg*s/m

Exclusion Criteria

• claustrophobia
• Postoperative TIMI grade 0-1
• Pregnancy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Henan Institute of Cardiovascular Epidemiology

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Muwei Li, MD

Role: STUDY_CHAIR

Fuwai central China cardiovascular hospotial

Central Contacts

Quan Guo

Role: CONTACT

xinyiguoquan@163.com

+8615670510031

Other Identifiers

HenanICE202301

Identifier Type: -

Identifier Source: org_study_id